243 research outputs found

    Finite temperature stability and dimensional crossover of exotic superfluidity in lattices

    Full text link
    We investigate exotic paired states of spin-imbalanced Fermi gases in anisotropic lattices, tuning the dimension between one and three. We calculate the finite temperature phase diagram of the system using real-space dynamical mean-field theory in combination with the quantum Monte Carlo method. We find that regardless of the intermediate dimensions examined, the Fulde-Ferrell-Larkin-Ovchinnikov (FFLO) state survives to reach about one third of the BCS critical temperature of the spin-density balanced case. We show how the gapless nature of the state found is reflected in the local spectral function. While the FFLO state is found at a wide range of polarizations at low temperatures across the dimensional crossover, with increasing temperature we find out strongly dimensionality-dependent melting characteristics of shell structures related to harmonic confinement. Moreover, we show that intermediate dimension can help to stabilize an extremely uniform finite temperature FFLO state despite the presence of harmonic confinement.Comment: 5 pages, 3 figure

    Disproportionate cardiac hypertrophy during early postnatal development in infants born preterm.

    Get PDF
    Background Adults born very preterm have increased cardiac mass and reduced function. We investigated whether a hypertrophic phenomenon occurs in later preterm infants and when this occurs during early development. Methods Cardiac ultrasound was performed on 392 infants (33% preterm at mean gestation 34±2 weeks). Scans were performed during fetal development in 137, at birth and 3 months of postnatal age in 200, and during both fetal and postnatal development in 55. Cardiac morphology and function was quantified and computational models created to identify geometric changes. Results At birth, preterm offspring had reduced cardiac mass and volume relative to body size with a more globular heart. By 3 months, ventricular shape had normalized but both left and right ventricular mass relative to body size were significantly higher than expected for postmenstrual age (left 57.8±41.9 vs. 27.3±29.4%, P<0.001; right 39.3±38.1 vs. 16.6±40.8, P=0.002). Greater changes were associated with lower gestational age at birth (left P<0.001; right P=0.001). Conclusion Preterm offspring, including those born in late gestation, have a disproportionate increase in ventricular mass from birth up to 3 months of postnatal age. These differences were not present before birth. Early postnatal development may provide a window for interventions relevant to long-term cardiovascular health

    BRS Pérola: cultivar de soja indicada para o Maranhão, Piauí e Tocantins.

    Get PDF
    Cultivares de soja com elevado potencial produtivo são requeridas todos os anos pelos agricultores. A Embrapa Soja vem desenvolvendo cultivares de soja produtivas e adaptadas às diferentes regiões edafoclimáticas do Brasil. O objetivo deste trabalho é apresentar a cultivar BRS Pérola, desenvolvida pela Embrapa Soja em convênio com a Fapcen, indicada para o cultivo nos estados do Maranhão, norte do Tocantins e sudoeste do Piauí. A BRS Pérola é uma cultivar de soja convencional, do grupo de maturidade relativo 8.8, tipo de crescimento determinado, flor branca, pubescência marrom médio e cor de hilo marrom. Nas safras 2007/08, 2008/09, 2009/10 e 2010/11 ela foi avaliada em experimentos de Valor de Cultivo e Uso em diferentes locais no MA, PI, TO, decidindo-se então pelo seu lançamento. A cultivar apresenta elevado potencial produtivo, ficando acima das três cultivares testemunhas utilizadas nos experimentos (BRS Tracajá, M-Soy 8866 e P98C81), com rendimento médio de 3.652 kg/ha, ao passo que a média das testemunhas foi de 3.436 kg/ha, indicando ainda resistência às principais doenças da soja e estabilidade na altura de plantas, proporcionando a sua semeadura em áreas de baixas altitudes. A BRS Pérola é uma excelente opção de cultivar de soja convencional para o mercado

    Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology

    Get PDF
    We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of the American Society of Clinical Oncology with the theme of "personalizing cancer care". We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. Adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2. Gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer. Octreotide LAR significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut. Addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor response but increased toxicities. Bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage II or III colon cancer. In patients with resected stage II colon cancer, recurrence score estimated by multigene RT-PCR assay has been shown to provide additional risk stratification. In stage IV colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site

    Role of LKB1 in lung cancer development

    Get PDF
    Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identified as frequently altered in lung cancer. LKB1, a kinase inactivated in 30% of lung cancers, is discussed in this review. Loss of LKB1 regulation often coincident with KRAS activation allows for unchecked growth and the metabolic capacity to accommodate the proliferation

    Nucleobindin Co-Localizes and Associates with Cyclooxygenase (COX)-2 in Human Neutrophils

    Get PDF
    The inducible cyclooxygenase isoform (COX-2) is associated with inflammation, tumorigenesis, as well as with physiological events. Despite efforts deployed in order to understand the biology of this multi-faceted enzyme, much remains to be understood. Nucleobindin (Nuc), a ubiquitous Ca2+-binding protein, possesses a putative COX-binding domain. In this study, we investigated its expression and subcellular localization in human neutrophils, its affinity for COX-2 as well as its possible impact on PGE2 biosynthesis. Complementary subcellular localization approaches including nitrogen cavitation coupled to Percoll fractionation, immunofluorescence, confocal and electron microscopy collectively placed Nuc, COX-2, and all of the main enzymes involved in prostanoid synthesis, in the Golgi apparatus and endoplasmic reticulum of human neutrophils. Immunoprecipitation experiments indicated a high affinity between Nuc and COX-2. Addition of human recombinant (hr) Nuc to purified hrCOX-2 dose-dependently caused an increase in PGE2 biosynthesis in response to arachidonic acid. Co-incubation of Nuc with COX-2-expressing neutrophil lysates also increased their capacity to produce PGE2. Moreover, neutrophil transfection with hrNuc specifically enhanced PGE2 biosynthesis. Together, these results identify a COX-2-associated protein which may have an impact in prostanoid biosynthesis

    Functional enhancer elements drive subclass-selective expression from mouse to primate neocortex

    Get PDF
    Viral genetic tools to target specific brain cell types in humans and non-genetic model organisms will transform basic neuroscience and targeted gene therapy. Here we used comparative epigenetics to identify thousands of human neuronal subclass-specific putative enhancers to regulate viral tools, and 34% of these were conserved in mouse. We established an AAV platform to evaluate cellular specificity of functional enhancers by multiplexed fluorescent in situ hybridization (FISH) and single cell RNA sequencing. Initial testing in mouse neocortex yields a functional enhancer discovery success rate of over 30%. We identify enhancers with specificity for excitatory and inhibitory classes and subclasses including PVALB, LAMP5, and VIP/LAMP5 cells, some of which maintain specificity in vivo or ex vivo in monkey and human neocortex. Finally, functional enhancers can be proximal or distal to cellular marker genes, conserved or divergent across species, and could yield brain-wide specificity greater than the most selective marker genes
    corecore